4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
15 citations
,
January 2020 in “RSC advances” The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.
April 2022 in “Reactions Weekly” February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes”
December 2023 in “Journal of Science Innovations and Nature of Earth” Tribulus terrestris may protect the liver from drug damage.
January 1983 in “Elsevier eBooks” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
30 citations
,
July 2009 in “Experimental and clinical endocrinology & diabetes” Cyproterone acetate effectively treats sexual disorders by reducing sexual functions and is generally well-tolerated.
Flutamide effectively treats female pattern hair loss long-term with low doses being safe for the liver.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
3 citations
,
May 2016 in “Gynecological Endocrinology” Low-dose flutamide improved hirsutism and satisfaction in women but had common side effects, causing some to stop treatment.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
1 citations
,
January 2021 in “Open Access Journal of Cancer & Oncology” Energy healing treatment improved flutamide's solubility and stability, potentially enhancing its effectiveness for prostate cancer.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
8 citations
,
November 1978 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.
50 citations
,
May 2000 in “Fertility and Sterility” Flutamide reduces hair growth better but has more side effects.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
25 citations
,
October 2008 in “Chromatographia” A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.